Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
In a study of 62 patients with advanced non-clear cell renal cell carcinoma, cabozantinib plus nivolumab achieved an objective response rate of 45.2% and a disease control rate of 93.6%.